Seijii Fukumoto

List of Publications by Year in descending order

201 papers	19,609 citations	14614 66 h-index	11288 136 g-index
265 all docs	265 docs citations	265 times ranked	11369 citing authors

#	Article	IF	Citations
1	Phosphate-Sensing. Advances in Experimental Medicine and Biology, 2022, 1362, 27-35.	0.8	3
2	Tumor-induced osteomalacia: a comprehensive clinical review of 895 cases. Bone Reports, 2022, 16, 101559.	0.2	0
3	Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23. Calcified Tissue International, 2021, 108, 104-115.	1.5	12
4	FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. Journal of Molecular Endocrinology, 2021, 66, R57-R65.	1.1	45
5	Incidence of Complications in 25 Adult Patients With X-linked Hypophosphatemia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3682-e3692.	1.8	21
6	Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. Journal of Bone and Mineral Metabolism, 2021, 39, 1066-1075.	1.3	15
7	Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span. Biochemistry and Biophysics Reports, 2021, 27, 101107.	0.7	10
8	Klothoâ€"the discovery of the FGF23 coreceptor. , 2021, , 225-231.		0
9	Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption. Bone Reports, 2021, 15, 101144.	0.2	7
10	FGF23 and Hypophosphatemic Rickets/Osteomalacia. Current Osteoporosis Reports, 2021, 19, 669-675.	1.5	8
11	Transcriptional Regulation of 25-Hydroxyvitamin D-24-Hydroxylase (CYP24A1) by Calcemic Factors in Keratinocytes. Journal of Nutritional Science and Vitaminology, 2021, 67, 424-428.	0.2	4
12	Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. Journal of Bone and Mineral Metabolism, 2020, 38, 70-77.	1.3	19
13	The Boneâ€"FGF23â€"Klotho Axis and Associated Diseases. , 2020, , 540-550.		0
14	Fibroblast growth factor 23. , 2020, , 1529-1538.		1
15	Approach to patients with hypophosphataemia. Lancet Diabetes and Endocrinology,the, 2020, 8, 163-174.	5.5	44
16	How do we sense phosphate to regulate serum phosphate level?. Journal of Bone and Mineral Metabolism, 2020, 38, 1-6.	1.3	4
17	Fibroblast growth factor receptor as a potential candidate for phosphate sensing. Current Opinion in Nephrology and Hypertension, 2020, 29, 446-452.	1.0	8
18	Phosphate-sensing and regulatory mechanism of FGF23 production. Journal of Endocrinological Investigation, 2020, 43, 877-883.	1.8	35

#	Article	IF	Citations
19	Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study. BMJ Open, 2020, 10, e036367.	0.8	4
20	Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. Journal of Bone and Mineral Metabolism, 2020, 38, 687-694.	1.3	4
21	Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. Journal of Bone and Mineral Research, 2020, 36, 262-270.	3.1	51
22	Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. Journal of Bone and Mineral Metabolism, 2020, 38, 141-144.	1.3	12
23	Dystrobrevin alpha gene is a direct target of the vitamin D receptor in muscle. Journal of Molecular Endocrinology, 2020, 64, 195-208.	1.1	5
24	Bone Impairment in a Large Cohort of Chinese Patients With Tumor-Induced Osteomalacia Assessed by HR-pQCT and TBS. Journal of Bone and Mineral Research, 2020, 37, 454-464.	3.1	13
25	Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. Journal of Bone and Mineral Research, 2020, 37, 1479-1488.	3.1	21
26	Phosphate Metabolism, Hyperphosphatemia, and Hypophosphatemia. , 2019, , 68-74.		0
27	Persistent Activation of Calciumâ€Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength. JBMR Plus, 2019, 3, e10182.	1.3	3
28	Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine, 2019, 45, 630-645.	2.7	61
29	Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature. Calcified Tissue International, 2019, 105, 476-486.	1.5	12
30	Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11418-11427.	3.3	106
31	FGF23 and Bone and Mineral Metabolism. Handbook of Experimental Pharmacology, 2019, 262, 281-308.	0.9	13
32	Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO). Bone Reports, 2019, 10, 100192.	0.2	15
33	Development of versatile non-homologous end joining-based knock-in module for genome editing. Scientific Reports, 2018, 8, 593.	1.6	36
34	X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocrine Reviews, 2018, 39, 274-291.	8.9	95
35	FGF23 beyond Phosphotropic Hormone. Trends in Endocrinology and Metabolism, 2018, 29, 755-767.	3.1	40
36	Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?. Frontiers in Endocrinology, 2018, 9, 48.	1.5	23

#	Article	IF	Citations
37	Incidence rate and characteristics of symptomatic vitamin D deficiency in children: a nationwide survey in Japan. Endocrine Journal, 2018, 65, 593-599.	0.7	12
38	Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones. Computer Assisted Surgery, 2017, 22, 14-19.	0.6	14
39	Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. International Orthopaedics, 2017, 41, 2597-2603.	0.9	15
40	Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions. Scientific Reports, 2017, 7, 7786.	1.6	29
41	Tumour-induced osteomalacia. Nature Reviews Disease Primers, 2017, 3, 17044.	18.1	204
42	Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. Endocrine Research, 2017, 42, 132-137.	0.6	53
43	Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. Journal of Bone and Mineral Metabolism, 2017, 35, 1-5.	1.3	82
44	Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23. Endocrine Journal, 2017, 64, 1033-1039.	0.7	15
45	Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A. Endocrine Journal, 2017, 64, 589-596.	0.7	4
46	Tumor-induced Osteomalacia Caused by a Parotid Tumor. Internal Medicine, 2017, 56, 535-539.	0.3	6
47	Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review. Internal Medicine, 2017, 56, 2455-2461.	0.3	1
48	Assessment criteria for vitamin D deficiency/insufficiency in Japan — proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocrine Journal, 2017, 64, 1-6.	0.7	39
49	Recent advances in the management of osteoporosis. F1000Research, 2017, 6, 625.	0.8	33
50	Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer. Internal Medicine, 2016, 55, 3623-3626.	0.3	2
51	High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. Endocrine Journal, 2016, 63, 479-484.	0.7	25
52	Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors. Endocrine Journal, 2016, 63, 397-404.	0.7	6
53	FGF23-Klotho axis in CKD. Renal Replacement Therapy, 2016, 2, .	0.3	7
54	ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors. Medical Molecular Morphology, 2016, 49, 203-209.	0.4	13

#	Article	IF	Citations
55	FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism. Calcified Tissue International, 2016, 98, 334-340.	1.5	38
56	Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. Journal of Bone and Mineral Metabolism, 2016, 34, 132-139.	1.3	48
57	Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocrine Journal, 2015, 62, 811-816.	0.7	124
58	Pathogenesis and diagnostic criteria for rickets and osteomalacia — Proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocrine Journal, 2015, 62, 665-671.	0.7	33
59	Rapid Recovery of Hypothalamic-Pituitary Axis after Successful Resection of an ACTH-secreting Neuroendocrine Tumor. Internal Medicine, 2015, 54, 2201-2205.	0.3	1
60	Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH). Journal of Bone and Mineral Research, 2015, 30, 1980-1993.	3.1	52
61	Oncogenic osteomalacia caused by an occult paranasal sinus tumor. Auris Nasus Larynx, 2015, 42, 167-169.	0.5	11
62	Pathogenesis and diagnostic criteria for rickets and osteomalaciaâ€”proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. Journal of Bone and Mineral Metabolism, 2015, 33, 467-473.	1.3	54
63	Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. Journal of Orthopaedic Science, 2015, 20, 765-771.	0.5	11
64	Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia. Endocrinology and Metabolism, 2014, 29, 136.	1.3	34
65	Anti-fibroblast growth factor 23 antibody therapy. Current Opinion in Nephrology and Hypertension, 2014, 23, 346-351.	1.0	21
66	Phosphate metabolism and vitamin D. BoneKEy Reports, 2014, 3, 497.	2.7	107
67	Functional Activities of Mutant Calcium-Sensing Receptors Determine Clinical Presentations in Patients With Autosomal Dominant Hypocalcemia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E363-E368.	1.8	27
68	Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney International, 2014, 85, 1103-1111.	2.6	158
69	What can FGF23 do without Klotho?. BoneKEy Reports, 2014, 3, 551.	2.7	1
70	Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. Bone, 2014, 67, 56-62.	1.4	59
71	Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia. Bone, 2014, 67, 145-151.	1.4	27
72	Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation. Journal of Bone and Mineral Metabolism, 2014, 32, 393-399.	1.3	24

#	Article	IF	Citations
73	Clinical Practice Guideline for the Management of Chronic Kidney Diseaseâ€Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 2013, 17, 247-288.	0.4	305
74	Clinical Aspects of Fibroblast Growth Factor 23. , 2013, , 151-166.		0
75	Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 67-76.	1.8	24
76	What's new in FGF23 research?. BoneKEy Reports, 2012, 1, 111.	2.7	2
77	Fibroblast Growth Factor 23-Related Osteomalacia Caused by the Prolonged Administration of Saccharated Ferric Oxide. Internal Medicine, 2012, 51, 2375-2378.	0.3	30
78	FGF23 as a Novel Therapeutic Target. Advances in Experimental Medicine and Biology, 2012, 728, 158-170.	0.8	10
79	Mutational analysis of patients with FGF23-related hypophosphatemic rickets. European Journal of Endocrinology, 2012, 167, 165-172.	1.9	31
80	Evaluation of a new automated chemiluminescence immunoassay for FGF23. Journal of Bone and Mineral Metabolism, 2012, 30, 217-221.	1.3	37
81	Kidney transplantation restored uncoupled bone turnover in end-stage renal disease. Clinical Nephrology, 2012, 78, 10-16.	0.4	3
82	A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone, 2011, 49, 913-916.	1.4	70
83	Osteomalacia Caused by Skull Base Tumors: Report of 2 Cases. Neurosurgery, 2011, 69, E239-E244.	0.6	15
84	Natural History of Mineral and Bone Disorders After Livingâ€Donor Kidney Transplantation: A Oneâ€Year Prospective Observational Study. Therapeutic Apheresis and Dialysis, 2011, 15, 481-487.	0.4	22
85	Fibroblast growth factor 23 as a phosphotropic hormone and beyond. Journal of Bone and Mineral Metabolism, 2011, 29, 507-514.	1.3	41
86	Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. Journal of Bone and Mineral Research, 2011, 26, 803-810.	3.1	99
87	Minireview: Fibroblast Growth Factor 23 in Phosphate Homeostasis and Bone Metabolism. Endocrinology, 2011, 152, 4-10.	1.4	77
88	The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrology Dialysis Transplantation, 2011, 26, 2691-2695.	0.4	30
89	Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis. Endocrine Journal, 2010, 57, 485-492.	0.7	54
90	Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumourâ€induced osteomalacia. Journal of Internal Medicine, 2010, 268, 390-394.	2.7	50

#	Article	IF	Citations
91	Runx1 and Runx2 cooperate during sternal morphogenesis. Development (Cambridge), 2010, 137, 1159-1167.	1.2	83
92	FGF23: Phosphate metabolism and beyond. IBMS BoneKEy, 2010, 7, 268-278.	0.1	11
93	Phosphate metabolism: Meeting report from the 32nd annual meeting of the American Society for bone and mineral research October 15-19, 2010 in Toronto, Ontario, Canada. IBMS BoneKEy, 2010, 7, 469-472.	0.1	0
94	Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, e57-e63.	1.6	25
95	Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney International, 2010, 78, 975-980.	2.6	279
96	Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. European Journal of Endocrinology, 2009, 161, 647-651.	1.9	29
97	A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism. Journal of Bone and Mineral Metabolism, 2009, 27, 386-389.	1.3	11
98	Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia. Journal of Bone and Mineral Research, 2009, 24, 1879-1888.	3.1	224
99	Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Bone, 2009, 45, 814-816.	1.4	127
100	Bone as an endocrine organ. Trends in Endocrinology and Metabolism, 2009, 20, 230-236.	3.1	256
101	The role of bone in phosphate metabolism. Molecular and Cellular Endocrinology, 2009, 310, 63-70.	1.6	25
102	A microRNA regulatory mechanism of osteoblast differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20794-20799.	3.3	273
103	Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. International Journal of Pediatric Endocrinology (Springer), 2009, 2009, 1-6.	1.6	27
104	Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. International Journal of Pediatric Endocrinology (Springer), 2009, 2009, 496514.	1.6	35
105	The distinct role of the Runx proteins in chondrocyte differentiation and intervertebral disc degeneration: Findings in murine models and in human disease. Arthritis and Rheumatism, 2008, 58, 2764-2775.	6.7	55
106	Anti-FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23. Journal of Bone and Mineral Research, 2008, 23, 1509-1518.	3.1	177
107	Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Bone, 2008, 42, 1235-1239.	1.4	188
108	Causes and Differential Diagnosis of Hypocalcemia -Recommendation Proposed by Expert Panel Supported by Ministry of Health, Labour and Welfare, Japan-. Endocrine Journal, 2008, 55, 787-794.	0.7	25

#	Article	IF	Citations
109	Actions and Mode of Actions of FGF19 Subfamily Members. Endocrine Journal, 2008, 55, 23-31.	0.7	114
110	Physiological Regulation and Disorders of Phosphate Metabolism -Pivotal Role of Fibroblast Growth Factor 23-. Internal Medicine, 2008, 47, 337-343.	0.3	99
111	Tumor-Induced Hypophosphatemic Osteomalacia Diagnosed by the Combinatory Procedures of Magnetic Resonance Imaging and Venous Sampling for FGF23. Internal Medicine, 2008, 47, 957-961.	0.3	35
112	Development of Tumor-induced Osteomalacia in a Subcutaneous Tumor, Defined by Venous Blood Sampling of Fibroblast Growth Factor-23. Internal Medicine, 2008, 47, 637-641.	0.3	29
113	Fibroblast Growth Factor (FGF)23 in Patients with Acromegaly. Endocrine Journal, 2007, 54, 481-484.	0.7	24
114	Fibroblast Growth Factor-23 (FGF23) in Patients with Transient Hypoparathyroidism: Its Important Role in Serum Phosphate Regulation. Endocrine Journal, 2007, 54, 465-470.	0.7	26
115	FGF23 is a hormone-regulating phosphate metabolismâ€"Unique biological characteristics of FGF23. Bone, 2007, 40, 1190-1195.	1.4	135
116	Central control of bone remodeling by neuromedin U. Nature Medicine, 2007, 13, 1234-1240.	15.2	177
117	Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clinical and Experimental Nephrology, 2007, 11, 255-257.	0.7	13
118	Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. Journal of Bone and Mineral Metabolism, 2007, 25, 419-422.	1.3	123
119	An Instructive Case Suggesting Cyclical Primary Hyperparathyroidism. Endocrine Journal, 2006, 53, 311-316.	0.7	5
120	Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature, 2006, 444, 770-774.	13.7	1,625
121	Hyperostosis-Hyperphosphatemia Syndrome: A Congenital Disorder of O-Glycosylation Associated With Augmented Processing of Fibroblast Growth Factor 23. Journal of Bone and Mineral Research, 2006, 22, 235-242.	3.1	147
122	Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. Journal of Cellular Biochemistry, 2006, 99, 196-208.	1.2	255
123	Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney International, 2005, 67, 1120-1125.	2.6	117
124	Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney International, 2005, 67, 1171-1178.	2.6	185
125	Post-translational Modification of Fibroblast Growth Factor 23. Therapeutic Apheresis and Dialysis, 2005, 9, 319-322.	0.4	32
126	Comparison of two assays for fibroblast growth factor (FGF)-23. Journal of Bone and Mineral Metabolism, 2005, 23, 435-440.	1.3	80

#	Article	IF	Citations
127	Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. American Journal of Physiology - Renal Physiology, 2005, 289, F1088-F1095.	1.3	309
128	A Novel Mutation in Fibroblast Growth Factor 23 Gene as a Cause of Tumoral Calcinosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5523-5527.	1.8	200
129	Fibroblast Growth Factor-23 in Patients with Gravesâ€™ Disease before and after Antithyroid Therapy: Its Important Role in Serum Phosphate Regulation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4211-4215.	1.8	31
130	Intravenous Calcitriol Therapy Increases Serum Concentrations of Fibroblast Growth Factor-23 in Dialysis Patients with Secondary Hyperparathyroidism. Nephron Clinical Practice, 2005, 101, c94-c99.	2.3	110
131	Venous Sampling for Fibroblast Growth Factor-23 Confirms Preoperative Diagnosis of Tumor-Induced Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3979-3982.	1.8	156
132	Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. European Journal of Endocrinology, 2004, 151, 55-60.	1.9	76
133	Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. American Journal of Kidney Diseases, 2004, 44, 250-256.	2.1	294
134	Ghrelin Directly Regulates Bone Formation. Journal of Bone and Mineral Research, 2004, 20, 790-798.	3.1	264
135	FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochemical and Biophysical Research Communications, 2004, 314, 409-414.	1.0	401
136	Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. Journal of Clinical Investigation, 2004, 113, 561-568.	3.9	1,244
137	Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. Journal of Clinical Investigation, 2004, 113, 561-568.	3.9	788
138	FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis. Journal of Bone and Mineral Research, 2003, 19, 429-435.	3.1	1,554
139	Receptor Tyrosine Kinases Inhibit Bone Morphogenetic Protein-Smad Responsive Promoter Activity and Differentiation of Murine MC3T3-E1 Osteoblast-like Cells. Journal of Bone and Mineral Research, 2003, 18, 827-835.	3.1	79
140	Decreased AP-1 Activity and Interleukin-11 Expression by Bone Marrow Stromal Cells May Be Associated With Impaired Bone Formation in Aged Mice. Journal of Bone and Mineral Research, 2003, 18, 1461-1470.	3.1	31
141	Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. Journal of Bone and Mineral Metabolism, 2003, 21, 166-171.	1.3	51
142	A Family of Autosomal Dominant Hypocalcemia with an Activating Mutation of Calcium-Sensing Receptor Gene.. Endocrine Journal, 2003, 50, 91-96.	0.7	21
143	Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in Vivo. Endocrinology, 2002, 143, 3179-3182.	1.4	395
144	A Family of Autosomal Dominant Hypocalcemia with a Positive Correlation between Serum Calcium and Magnesium: Identification of a Novel Gain of Function Mutation (Ser⁸²⁰Phe) in the Calcium-Sensing Receptor. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2681-2687.	1.8	22

#	Article	IF	Citations
145	Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice. Journal of Biological Chemistry, 2002, 277, 49011-49018.	1.6	131
146	Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Current Opinion in Nephrology and Hypertension, 2002, 11, 385-389.	1.0	70
147	Marked Hypercalcemia in a Patient with Hypocalciuric Hypercalcemia without a Mutation in the Calcium-Sensing Receptor Gene.. Internal Medicine, 2002, 41, 1153-1157.	0.3	2
148	Clonal Endothelial Cells Produce Humoral Factors that Inhibit Osteoclast-Like Cell Formation In Vitro.. Endocrine Journal, 2002, 49, 439-447.	0.7	15
149	Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4957-4960.	1.8	621
150	Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet, The, 2002, 360, 692-694.	6.3	368
151	Stimulation of Smad1 Transcriptional Activity by Ras-Extracellular Signal-Regulated Kinase Pathway: A Possible Mechanism for Collagen-Dependent Osteoblastic Differentiation. Journal of Bone and Mineral Research, 2002, 17, 240-248.	3.1	84
152	Parathyroid Hormone-Related Protein Induced Coupled Increases in Bone Formation and Resorption Markers for 7 Years in a Patient With Malignant Islet Cell Tumors. Journal of Bone and Mineral Research, 2002, 17, 753-757.	3.1	7
153	Effects of 1-year treatment with fluvastatin or pravastatin on bone. American Journal of Medicine, 2001, 110, 584-587.	0.6	49
154	Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6500-6505.	3.3	1,321
155	Inactivating Mutations of Calcium-Sensing Receptor Results in Parathyroid Lipohyperplasia. Diagnostic Molecular Pathology, 2001, 10, 242-247.	2.1	34
156	Fibroblast Growth Factor (FGF)-23 and Hypophosphatemic Rickets/Osteomalacia.. Endocrine Journal, 2001, 48, 603-610.	0.7	8
157	Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo. Journal of Bone and Mineral Metabolism, 2001, 19, 207-212.	1.3	17
158	Focal Adhesion Kinase Activity Is Required for Bone Morphogenetic Protein-Smad1 Signaling and Osteoblastic Differentiation in Murine MC3T3-E1 Cells. Journal of Bone and Mineral Research, 2001, 16, 1772-1779.	3.1	98
159	GH Inhibits Interferon-Î³-Induced Signal Transducer and Activator of Transcription-1 Activation and Expression of the Inducible Isoform of Nitric Oxide Synthase in INS-1 Cells. Endocrinology, 2001, 142, 3909-3916.	1.4	13
160	Cloning and Characterization of Two Promoters for the Human Calcium-sensing Receptor (CaSR) and Changes of CaSR Expression in Parathyroid Adenomas. Journal of Biological Chemistry, 2000, 275, 7553-7557.	1.6	77
161	Interactions between Cancer and Bone Marrow Cells Induce Osteoclast Differentiation Factor Expression and Osteoclast-like Cell Formation in Vitro. Biochemical and Biophysical Research Communications, 2000, 267, 632-637.	1.0	90
162	Vitamin K2 inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone, 2000, 27, 769-776.	1.4	71

#	Article	IF	Citations
163	No Enzyme Activity of 25-Hydroxyvitamin D3 1Î±-Hydroxylase Gene Product in Pseudovitamin D Deficiency Rickets, Including That with Mild Clinical Manifestation. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4111-4117.	1.8	72
164	Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro1. Endocrinology, 1999, 140, 5060-5065.	1.4	97
165	HeterozygousgspMutation Renders Ion Channels of Human Somatotroph Adenoma Cells Unresponsive to Growth Hormone-Releasing Hormone1. Endocrinology, 1999, 140, 2018-2026.	1.4	14
166	Stimulation of Osteoclast Formation by 1,25-Dihydroxyvitamin D Requires Its Binding to Vitamin D Receptor (VDR) in Osteoblastic Cells: Studies Using VDR Knockout Mice. Endocrinology, 1999, 140, 1005-1008.	1.4	164
167	A Novel Activating Mutation in Calcium-Sensing Receptor Gene Associated with a Family of Autosomal Dominant Hypocalcemia1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 363-366.	1.8	58
168	An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. Clinical Endocrinology, 1999, 50, 537-543.	1.2	59
169	Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone, 1999, 25, 375-377.	1.4	75
170	Extracellular Matrix-Associated Bone Morphogenetic Proteins Are Essential for Differentiation of Murine Osteoblastic Cellsin Vitro¹. Endocrinology, 1999, 140, 2125-2133.	1.4	138
171	Short-Term Treatment with Troglitazone Decreases Bone Turnover in Patients with Type 2 Diabetes Mellitus.. Endocrine Journal, 1999, 46, 795-801.	0.7	54
172	A Novel Activating Mutation in Calcium-Sensing Receptor Gene Associated with a Family of Autosomal Dominant Hypocalcemia. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 363-366.	1.8	51
173	No Enzyme Activity of 25-Hydroxyvitamin D3 1Â-Hydroxylase Gene Product in Pseudovitamin D Deficiency Rickets, Including That with Mild Clinical Manifestation. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4111-4117.	1.8	67
174	Reduced Expression of Interleukin-11 in Bone Marrow Stromal Cells of Senescence-Accelerated Mice (SAMP6): Relationship to Osteopenia with Enhanced Adipogenesis. Journal of Bone and Mineral Research, 1998, 13, 1370-1377.	3.1	76
175	Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene: Absence of mutation in patients with pseudohypoparathyroidism type Ib1Presented in part at the Annual Meeting of the American Society of Bone and Mineral Research, September, 1996.12The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL and GenBank nucleotide sequence databases with the following accession number AB006200 and AB006201.2. Molecular and Cellular Endocrinology, 1998, 141, 41-47.	1.6	17
176	Effect of Mechanical Unloading and Reloading on Periosteal Bone Formation and Gene Expression in Tail-Suspended Rapidly Growing Rats. Bone, 1998, 22, 89S-93S.	1.4	66
177	Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2915-2920.	1.8	122
178	A New Synthetic Steroid, Osaterone Acetate (TZP-4238), Increases Cortical Bone Mass and Strength by Enhancing Bone Formation in Ovariectomized Rats. Journal of Bone and Mineral Research, 1997, 12, 590-597.	3.1	15
179	Inhibition of Bone Resorption by Pamidronate Cannot Restore Normal Gain in Cortical Bone Mass and Strength in Tail-Suspended Rapidly Growing Rats. Journal of Bone and Mineral Research, 1997, 12, 1058-1067.	3.1	68
180	Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2915-2920.	1.8	102

#	Article	IF	Citations
181	Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 607-611.	1.8	60
182	Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2554-2558.	1.8	58
183	Relationship between actions of transforming growth factor (TGF)-? and cell surface expression of its receptors in clonal osteoblastic cells. Journal of Cellular Physiology, 1995, 162, 315-321.	2.0	45
184	Assay of serum pyridinoline: a potential marker for bone resorption. Clinica Chimica Acta, 1995, 235, 221-227.	0.5	15
185	Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. Biochimica Et Biophysica Acta - General Subjects, 1994, 1201, 223-228.	1.1	23
186	Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 165-170.	1.8	14
187	Transforming growth factor Î² stimulation of parathyroid hormone-related protein (PTHrP): A paracrine regulator?. Molecular and Cellular Endocrinology, 1993, 92, 55-62.	1.6	88
188	Transforming growth factor Î² stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?. Molecular and Cellular Endocrinology, 1993, 94, 145.	1.6	3
189	Plasminogen activator regulation in osteoblasts: Parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. Journal of Cellular Physiology, 1992, 152, 346-355.	2.0	37
190	Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. Journal of Cellular Physiology, 1991, 149, 34-43.	2.0	59
191	Pheochromocytoma with Pyrexia and Marked Inflammatory Signs: A Paraneoplastic Syndrome with Possible Relation to Interleukin-6 Production*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 877-881.	1.8	65
192	Usefulness of Nude Rats in Studies on Characteristics of Human Cancers. , 1989, , 220-226.		0
193	Parathyroid Hormone-Related Protein in Adult T-Cell Leukemia-Lymphoma. Annals of Internal Medicine, 1989, 111, 484.	2.0	87
194	Suppression of Serum 1,25-Dihydroxyvitamin D in Humoral Hypercalcemia of Malignancy Is Caused by Elaboration of a Factor That Inhibits Renal 1,25- Dihydroxyvitamin D₃Production*. Endocrinology, 1989, 124, 2057-2062.	1.4	55
195	Effect of 24,25-Dihydroxyvitamin D₃on 1,25- Dihydroxyvitamin D₃[1,25-(OH)₂D₃] Metabolism in Vitamin D-Deficient Rats Infused with 1,25-(OH)₂D₃*. Endocrinology, 1989, 124, 511-517.	1.4	21
196	A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy. Calcified Tissue International, 1988, 43, 97-102.	1.5	26
197	Expression of parathyroid hormone-related protein in a human T cell lymphotrophic virus type I-infected T cell line. Biochemical and Biophysical Research Communications, 1988, 154, 1182-1188.	1.0	70
198	Clinical Evaluation of Calcium Metabolism in Adult T-Cell Leukemia/Lymphoma. Archives of Internal Medicine, 1988, 148, 921.	4.3	72

#	Article	IF	Citations
199	Renal Magnesium Wasting in a Patient with Short Bowel Syndrome with Magnesium Deficiency: Effect of 1Î±-Hydroxyvitamin D3Treatment*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1301-1304.	1.8	21
200	Stimulation of Osteoclast Formation by 1,25-Dihydroxyvitamin D Requires Its Binding to Vitamin D Receptor (VDR) in Osteoblastic Cells: Studies Using VDR Knockout Mice. , 0, .		41
201	Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in Vivo. , 0, .		121